ACADIA Pharmaceuticals Inc. (ACAD) is around the top of the Biotechnology industry according to InvestorsObserver. ACAD received an overall rating of 64, which means that it scores higher than 64 percent of all stocks. ACADIA Pharmaceuticals Inc. also achieved a score of 74 in the Biotechnology industry, putting it above 74 percent of Biotechnology stocks. Biotechnology is ranked 14 out of the 148 industries.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
What's Happening With ACADIA Pharmaceuticals Inc. Stock Today?
ACADIA Pharmaceuticals Inc. (ACAD) stock has fallen -1.85% while the S&P 500 is unchanged 0% as of 10:47 AM on Wednesday, Apr 8. ACAD has fallen -$0.77 from the previous closing price of $41.71 on volume of 124,405 shares. Over the past year the S&P 500 is down -7.60% while ACAD has risen 53.51%. ACAD lost -$1.60 per share the over the last 12 months.
